Eslicarbazepine acetate is a third-generation anti-epileptic prodrug quickly and extensively
transformed to eslicarbazepine after oral administration. Reduction in seizure frequency in …

Eslicarbazepine acetate is a third-generation anti-epileptic prodrug quickly and extensively
transformed to eslicarbazepine after oral administration. Reduction in seizure frequency in …

Epilepsy is a common chronic neurological condition affecting 50 million people worldwide.
Because at least 30% of patients with partial seizures do not achieve seizure control with the …

Eslicarbazepine acetate (ESL) is a novel once‐daily antiepileptic drug (AED) approved in
Europe since 2009 that was found to be efficacious and well tolerated in a phase III clinical …

Abstract Background: Eslicarbazepine acetate (Zebenix®) is a voltage-gated sodium
channel blocker approved in 2009 by the European Medicines Agency as adjunctive …

Background Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED), still
insufficiently studied regarding pharmacokinetic variability, efficacy and tolerability. The …

Human arylacetamide deacetylase (AADAC) plays a role in the detoxification or activation of
drugs and is sometimes involved in the incidence of toxicity by catalyzing hydrolysis …

Purpose To compare the bioavailability (BA) and pharmacokinetic (PK) properties and to
demonstrate the bioequivalence (BE) between two active product ingredient (API) sources of …

Objectives Eslicarbazepine acetate (ESL) is a once‐daily (QD) oral antiepileptic drug (AED)
for focal‐onset seizures (FOS). Pharmacokinetic (PK) and pharmacodynamic (PD) models …

Objective: Antiepileptic drugs are often used in patients with some degree of renal
impairment. The objective of this study was to evaluate the effect of renal function on the …